DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Doi.org Make Money
Keywords
Topics
Questions
Schema
External Links
Analytics And Tracking
Libraries
Hosting Providers
CDN Services

We began analyzing https://link.springer.com/article/10.1007/s10552-011-9867-8, but it redirected us to https://link.springer.com/article/10.1007/s10552-011-9867-8. The analysis below is for the second page.

Title[redir]:
Why mammography screening has not lived up to expectations from the randomised trials | Cancer Causes & Control
Description:
We analysed the relation between tumour sizes and stages and the reported effects on breast cancer mortality with and without screening in trials and observational studies. The average tumour sizes in all the trials suggest only a 12% reduction in breast cancer mortality, which agrees with the 10% reported in the most reliable trials. Recent studies of tumour sizes and tumour stages show that screening has not lowered the rate of advanced cancers. In agreement with this, recent observational studies of breast cancer mortality have failed to find an effect of screening. In contrast, screening leads to serious harms in healthy women through overdiagnosis with subsequent overtreatment and false-positive mammograms. We suggest that the rationale for breast screening be urgently reassessed by policy-makers. The observed decline in breast cancer mortality in many countries seems to be caused by improved adjuvant therapy and breast cancer awareness, not screening. We also believe it is more important to reduce the incidence of cancer than to detect it ‘early.’ Avoiding getting screening mammograms reduces the risk of becoming a breast cancer patient by one-third.

Matching Content Categories {📚}

Health & Fitness
Education
Movies

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🏙️ Massive Traffic: 50M - 100M visitors per month

Based on our best estimate, this website will receive around 96,105,781 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We can't see how the site brings in money.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Doi.org might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

cancer, breast, screening, google, scholar, article, pubmed, mammography, cas, mortality, gøtzsche, med, trials, overdiagnosis, lancet, mammographic, zahl, jørgensen, health, tumour, incidence, bmj, oncol, trial, tabar, swedish, duffy, privacy, cookies, content, data, randomised, mæhlen, effect, access, rates, study, author, fagerberg, results, analysis, information, publish, search, control, review, peter, cancers, women, mammograms,

Topics {✒️}

karsten juhl jørgensen month download article/chapter population-based screening-program view mammographic screening lymph node status uk/anz dcis trial pre-mammography screening period average tumour sizes early breast cancer tumour stages show full article pdf privacy choices/manage cookies breast cancer mortality breast-cancer mortality author information authors breast cancer screening keyword breast cancer awareness breast cancer patient invasive breast cancer breast cancer atypia breast cancer diagnosed spotting breast cancer organised mammography screening tumour sizes tumor size screening mammograms reduces breast cancer patients tumour development hampshire mammography network article cancer interval breast carcinomas related subjects medical decision making brystkreftdødelighet og validititet ullevål university hospital nordic cochrane centre false-positive mammograms breast cancers detected european economic area cancer rates decline check access similar access instant access conditions privacy policy human malignant tumors swedish national board randomized screening trial article gøtzsche mammographic screening justifiable

Questions {❓}

Gøtzsche PC, Olsen O (2000) Is screening for breast cancer with mammography justifiable?
Jørgensen KJ, Keen JD, Gøtzsche PC (2011) Is mammographic screening justifiable considering its substantial overdiagnosis rate and minor effect on mortality?
Paci E, Warwick J, Falini P, Duffy SW (2004) Overdiagnosis in screening: is the increase in breast cancer incidence rates a cause for concern?
Rostgaard K, Vaeth M, Rootzén H, Lynge E (2010) Why did the breast cancer lymph node status distribution improve in Denmark in the pre-mammography screening period of 1978–1994?
Smith RA, Duffy SW, Gabe R et al (2004) The randomized trials of breast cancer screening: what have we learned?
By the year 2015?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Why mammography screening has not lived up to expectations from the randomised trials
         description:We analysed the relation between tumour sizes and stages and the reported effects on breast cancer mortality with and without screening in trials and observational studies. The average tumour sizes in all the trials suggest only a 12% reduction in breast cancer mortality, which agrees with the 10% reported in the most reliable trials. Recent studies of tumour sizes and tumour stages show that screening has not lowered the rate of advanced cancers. In agreement with this, recent observational studies of breast cancer mortality have failed to find an effect of screening. In contrast, screening leads to serious harms in healthy women through overdiagnosis with subsequent overtreatment and false-positive mammograms. We suggest that the rationale for breast screening be urgently reassessed by policy-makers. The observed decline in breast cancer mortality in many countries seems to be caused by improved adjuvant therapy and breast cancer awareness, not screening. We also believe it is more important to reduce the incidence of cancer than to detect it ‘early.’ Avoiding getting screening mammograms reduces the risk of becoming a breast cancer patient by one-third.
         datePublished:2011-11-10T00:00:00Z
         dateModified:2011-11-10T00:00:00Z
         pageStart:15
         pageEnd:21
         sameAs:https://doi.org/10.1007/s10552-011-9867-8
         keywords:
            Tumour size
            Tumour stage
            Mammography screening
            Overdiagnosis
            Breast cancer mortality
            Cancer Research
            Biomedicine
            general
            Oncology
            Public Health
            Epidemiology
            Hematology
         image:
         isPartOf:
            name:Cancer Causes & Control
            issn:
               1573-7225
               0957-5243
            volumeNumber:23
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Netherlands
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Peter C. Gøtzsche
               affiliation:
                     name:The Nordic Cochrane Centre
                     address:
                        name:The Nordic Cochrane Centre, Copenhagen, Denmark
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Karsten Juhl Jørgensen
               affiliation:
                     name:The Nordic Cochrane Centre
                     address:
                        name:The Nordic Cochrane Centre, Copenhagen, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Per-Henrik Zahl
               affiliation:
                     name:Norwegian Institute of Public Health
                     address:
                        name:Norwegian Institute of Public Health, Oslo, Norway
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jan Mæhlen
               affiliation:
                     name:Ullevål University Hospital
                     address:
                        name:Department of Pathology, Ullevål University Hospital, Oslo, Norway
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Why mammography screening has not lived up to expectations from the randomised trials
      description:We analysed the relation between tumour sizes and stages and the reported effects on breast cancer mortality with and without screening in trials and observational studies. The average tumour sizes in all the trials suggest only a 12% reduction in breast cancer mortality, which agrees with the 10% reported in the most reliable trials. Recent studies of tumour sizes and tumour stages show that screening has not lowered the rate of advanced cancers. In agreement with this, recent observational studies of breast cancer mortality have failed to find an effect of screening. In contrast, screening leads to serious harms in healthy women through overdiagnosis with subsequent overtreatment and false-positive mammograms. We suggest that the rationale for breast screening be urgently reassessed by policy-makers. The observed decline in breast cancer mortality in many countries seems to be caused by improved adjuvant therapy and breast cancer awareness, not screening. We also believe it is more important to reduce the incidence of cancer than to detect it ‘early.’ Avoiding getting screening mammograms reduces the risk of becoming a breast cancer patient by one-third.
      datePublished:2011-11-10T00:00:00Z
      dateModified:2011-11-10T00:00:00Z
      pageStart:15
      pageEnd:21
      sameAs:https://doi.org/10.1007/s10552-011-9867-8
      keywords:
         Tumour size
         Tumour stage
         Mammography screening
         Overdiagnosis
         Breast cancer mortality
         Cancer Research
         Biomedicine
         general
         Oncology
         Public Health
         Epidemiology
         Hematology
      image:
      isPartOf:
         name:Cancer Causes & Control
         issn:
            1573-7225
            0957-5243
         volumeNumber:23
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Netherlands
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Peter C. Gøtzsche
            affiliation:
                  name:The Nordic Cochrane Centre
                  address:
                     name:The Nordic Cochrane Centre, Copenhagen, Denmark
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Karsten Juhl Jørgensen
            affiliation:
                  name:The Nordic Cochrane Centre
                  address:
                     name:The Nordic Cochrane Centre, Copenhagen, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Per-Henrik Zahl
            affiliation:
                  name:Norwegian Institute of Public Health
                  address:
                     name:Norwegian Institute of Public Health, Oslo, Norway
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jan Mæhlen
            affiliation:
                  name:Ullevål University Hospital
                  address:
                     name:Department of Pathology, Ullevål University Hospital, Oslo, Norway
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Causes & Control
      issn:
         1573-7225
         0957-5243
      volumeNumber:23
Organization:
      name:Springer Netherlands
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The Nordic Cochrane Centre
      address:
         name:The Nordic Cochrane Centre, Copenhagen, Denmark
         type:PostalAddress
      name:The Nordic Cochrane Centre
      address:
         name:The Nordic Cochrane Centre, Copenhagen, Denmark
         type:PostalAddress
      name:Norwegian Institute of Public Health
      address:
         name:Norwegian Institute of Public Health, Oslo, Norway
         type:PostalAddress
      name:Ullevål University Hospital
      address:
         name:Department of Pathology, Ullevål University Hospital, Oslo, Norway
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Peter C. Gøtzsche
      affiliation:
            name:The Nordic Cochrane Centre
            address:
               name:The Nordic Cochrane Centre, Copenhagen, Denmark
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Karsten Juhl Jørgensen
      affiliation:
            name:The Nordic Cochrane Centre
            address:
               name:The Nordic Cochrane Centre, Copenhagen, Denmark
               type:PostalAddress
            type:Organization
      name:Per-Henrik Zahl
      affiliation:
            name:Norwegian Institute of Public Health
            address:
               name:Norwegian Institute of Public Health, Oslo, Norway
               type:PostalAddress
            type:Organization
      name:Jan Mæhlen
      affiliation:
            name:Ullevål University Hospital
            address:
               name:Department of Pathology, Ullevål University Hospital, Oslo, Norway
               type:PostalAddress
            type:Organization
PostalAddress:
      name:The Nordic Cochrane Centre, Copenhagen, Denmark
      name:The Nordic Cochrane Centre, Copenhagen, Denmark
      name:Norwegian Institute of Public Health, Oslo, Norway
      name:Department of Pathology, Ullevål University Hospital, Oslo, Norway
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(210)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

Emails and Hosting {✉️}

Mail Servers:

mx.zoho.eu
mx2.zoho.eu
mx3.zoho.eu

Name Servers:

josh.ns.cloudflare.com
zita.ns.cloudflare.com

CDN Services {📦}

Crossref

5.37s.